$Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation$

Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Bibliographic Details
Main Authors:	B. Wake, C. Hyde, S. Bryan, P. Barton, F. Song, A. Fry-Smith, C. Davenport
Format:	Article
Language:	English
Published:	NIHR Journals Library 2002-01-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta6030

Similar Items

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

Maintenance rituximab in Veterans with follicular lymphoma
by: Ahmad S. Halwani, et al.
Published: (2020-10-01)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
by: Lali V, et al.
Published: (2006-12-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
by: Ulrich Dührsen, et al.
Published: (2018-07-01)

Rituximab in the treatment of non-Hodgkin&rsquo;s lymphoma
by: Beate Hauptrock, et al.
Published: (2008-09-01)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
by: Dennis A Eichenauer, et al.
Published: (2009-07-01)

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX
by: Hamdy Zawam, et al.
Published: (2018-06-01)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
by: Martina Bogeljić Patekar, et al.
Published: (2017-01-01)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
by: Aguiar-Bujanda D, et al.
Published: (2015-10-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
by: Lee YP, et al.
Published: (2021-05-01)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
by: Hee Kyung Kim, et al.
Published: (2020-01-01)

Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
by: Camila Bezerra Melo Figueirêdo, et al.
Published: (2014-09-01)

Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma
by: Eva Fernández Cañabate, et al.
Published: (2018-01-01)

Cytogenetic and molecular analysis of follicular non-Hodgkin's lymphoma
by: Turner, G. E.
Published: (1992)

The role of tazemetostat in relapsed/refractory follicular lymphoma
by: Gottfried von Keudell, et al.
Published: (2021-05-01)

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
by: D Papaioannou, et al.
Published: (2012-10-01)

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma
by: Klaus Herfarth, et al.
Published: (2018-12-01)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
by: Subramanian J, et al.
Published: (2017-04-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

New agents in relapsed/refractory Hodgkin's lymphoma
by: Irene Biasoli, et al.

Aggressive Non-Hodgkin's Lymphoma: therapeutic considerations of pre rituximab era
by: Carmino Antônio de Souza
Published: (2005-10-01)

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
by: Claudio Fozza, et al.
Published: (2011-01-01)

Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation
by: C Knight, et al.
Published: (2004-09-01)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
by: Dawson, K., et al.
Published: (2021)

Composite t(14;18)-Negative Follicular Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma
by: John Patrick O’Neill, et al.
Published: (2018-01-01)

Rituximab for primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp
by: Čolović Nataša, et al.
Published: (2008-01-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
by: Hung-Bo Wu, et al.
Published: (2013-01-01)

Rituximab treatment in a spondyloarthritis patient with low-grade follicular lymphoma: a case report
by: Patrícia Martins, et al.
Published: (2020-07-01)

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
by: Mensah FA, et al.
Published: (2018-08-01)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
by: Zinzani Pier, et al.
Published: (2012-10-01)

An approach for conjugation of 177 Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
by: Parul Thakral, et al.
Published: (2014-01-01)

Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
by: Monika Enqvist, et al.
Published: (2019-09-01)